This study aimed to investigate the efficacy of Nimesulide and Diclofenac sodium for gout management.
Compared to Diclofenac (75 mg twice daily), Nimesulide (100 mg twice daily) shows a better analgesic effect in gout-affected people.
This study aimed to investigate the efficacy of Nimesulide and Diclofenac sodium for gout management.
The study consisted of 40 volunteers diagnosed with gout, comprising 33 males and 7 females. Participants were segregated into two groups. The first group, referred to as the "main group," comprised 20 gout subjects who were administered Nimesulide tablets at a dosage of 100 mg twice daily.
In order to assess the efficacy of Nimesulide, the second group (referred to as the "control group") received Diclofenac sodium at a dosage of 75 mg twice daily. Both groups followed the therapeutic regimen for a duration of 7 days.
Nimesulide tablets demonstrated the highest efficacy in terms of both the speed and intensity of the analgesic effect. Within 20 minutes, 7 subjects in the first group reported a decrease in joint pain, which increased to 13 subjects post 40 minutes. After one hour, 16 people in the first group rated the effect as good, with a significant reduction in pain observed in 6 of them.
Conversely, in the second group, only 3 subjects experienced a decline in pain, and that too after 1-1.5 hours. All volunteers in the first group acknowledged the anti-inflammatory and analgesic effect of Nimesulide tablets, while only 2 subjects in the second group experienced the effect of Diclofenac. Nimesulide successfully halted arthritis attack in 45% of people (n = 9) in the first group, compared to only 10% of people (n = 2) in the second group.
For gout management, Nimesulide has better effectiveness when compared to Diclofenac.
Asian Journal of Pharmaceutical and Biological Research
Comparative effectiveness of Nimesulide and Diclofenac sodium in gout
Nigora Mavlonovna Umurova
Comments (0)